Aggregate (Aug 2024)

Ultrabright NIR AIEgen nanoparticles‐enhanced lateral flow immunoassay platform for accurate diagnostics of complex samples

  • Jia Shu,
  • Yujian Li,
  • Huan Cai,
  • Qing Fu,
  • Chunyang Li,
  • Jianbo Yuan,
  • Yan Zhao,
  • Changjin Liu,
  • Haiping Wu,
  • Doudou Ling,
  • Zhangluxi Liu,
  • Guannan Su,
  • Qingfeng Cao,
  • Xiaolin Huang,
  • Rui Chen,
  • Peizeng Yang

DOI
https://doi.org/10.1002/agt2.551
Journal volume & issue
Vol. 5, no. 4
pp. n/a – n/a

Abstract

Read online

Abstract Accurate and sensitive near‐infrared (NIR) luminescent lateral flow immunoassay (LFIA) has attracted considerable attention in the field of point‐of‐care testing (POCT). However, the detection accuracy and sensitivity are often compromised by the low fluorescence quantum efficiency ( 800 nm) completely eliminated background interference and allowed highly accurate and sensitive detection without any pre‐treatment steps. The limits of detection (LODs) for aflatoxin B1 (AFB1) in soy sauce, alpha hemolysin (Hla) of Staphylococcus aureus biomarker in joint fluid, and C‐reactive protein (CRP) in human haemolysed samples were 0.01 ng mL−1, 0.02 µg mL−1, and 0.156 mg L−1, respectively, commensurating with those of the corresponding gold standard assays and covering the detection range of interests. It is anticipated that the ultrabright NIR AIEgen nanoparticles will serve as a universally applicable signal probe for NIR‐LFIA diagnostics, promising to expand the range of applications for quantitative detection of complex samples.

Keywords